NASDAQ · Biotechnology
Celldex Therapeutics, Inc. (CLDX) Stock
$30.01
+2.42%
NASDAQ: CLDX
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Celldex Therapeutics CFO Plans to Retire in 2027
MT Newswires · Jul 15, 2026
Celldex Announces Planned Transition of Chief Financial Officer
GlobeNewswire · Jul 15, 2026
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?
Insider Monkey · Jun 30, 2026
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
PR Newswire · Jun 24, 2026
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
InvestorPlace · Jun 19, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held0.27%
Institutions Held95.89%
Institutions Float Held96.15%
Peer Comparison
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. (CLDX) stock trades at $30.01 with a market capitalization of $2.00B. The stock is valued at a price-to-earnings (P/E) ratio of -7.26, price-to-book of 3.45, price-to-sales of 18803.06. Over the past 52 weeks the stock has ranged between $22.10 and $45.14, and currently trades 33.5% below its 52-week high.
On profitability, Celldex Therapeutics, Inc. generates a return on equity (ROE) of -52.36%, return on capital employed of -45.19%, an operating margin of -14350.00%, a net profit margin of -345.96%.